Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDC-3280 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: GDC-3280 | EXPERIMENTAL | Participants in multiple cohorts and treatment periods will receive single doses of GDC-3280 under fed/fasting conditions. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants in multiple cohorts and treatment periods will receive single doses of placebo under fed/fasting conditions. |
| Part B: GCD-3280 | EXPERIMENTAL | Participants in different cohorts will receive GDC-3280 in multiple ascending doses under fed/fasting conditions.\\n |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants in different cohorts will receive placebo in multiple ascending doses under fed/fasting conditions.\\n |
| Name | Type | Description |
|---|---|---|
| GDC-3280 | DRUG | GDC-3280 at various doses, depending on the cohort and treatment period |
| Placebo | DRUG | Placebo at various doses, depending on the cohort and treatment period |
Inclusion Criteria: * Is male or female, using highly effective contraception * Has a body mass index (BMI) 18.0 to 30.0 kg/m2, inclusive * Is in good general health * Having signed informed consent, is willing and able to comply with requirements of the study Exclusion Criteria: * Does not satis...
GDC-3280 is an investigational small molecule being developed by Roche Holding AG (RHHBY). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and the only completed trial was a safety, tolerability, and pharmacokinetic study.
GDC-3280 is being studied for use in healthy volunteers. It is an investigational small molecule in Phase 1 clinical development. The completed trial focused on assessing its safety, tolerability, and pharmacokinetics in healthy participants.
GDC-3280 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and tolerability in healthy volunteers.
GDC-3280 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The only trial conducted was a Phase 1 study in healthy volunteers, which has been completed.
GDC-3280 has one completed clinical trial, NCT02471859, titled "A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants." This Phase 1 study enrolled 8 participants in the United Kingdom and was placebo-controlled, randomized, and double-blind.